BN82451 / Ipsen - LARVOL DELTA

Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients (clinicaltrials.gov) - P2a; N=30; Recruiting; Sponsor: Ipsen; Trial primary completion date: Dec 2015 ➔ Dec 2016

Trial primary completion date • Biosimilar